Eldad Klaiman

Name: dblp XML data dump
Creator: Schloss Dagstuhl - Leibniz Center for Informatics
Published: 1993
License: https://creativecommons.org/publicdomain/zero/1.0/
Keywords: dblp, XML, computer science, scholarly publications, metadata

◀ ▶ joint publications with Ming Feng

> Home > Persons > Eldad Klaiman

Publications

2022
[j3]
- view
  - electronic edition via DOI (open access)
  - details & citations
  authority control:
- export record
  dblp key:
  - journals/jimaging/Conde-SousaVFXW22
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/jimaging/Conde-SousaVFXW22
Eduardo Conde-Sousa, João Vale, Ming Feng, Kele Xu, Yin Wang, Vincenzo Della Mea, David La Barbera, Ehsan Montahaei, Mahdieh Soleymani Baghshah, Andreas Turzynski, Jacob Gildenblat, Eldad Klaiman, Yiyu Hong, Guilherme Aresta, Teresa Araújo, Paulo Aguiar, Catarina Eloy, António Polónia:
HEROHE Challenge: Predicting HER2 Status in Breast Cancer from Hematoxylin-Eosin Whole-Slide Imaging. J. Imaging 8(8): 213 (2022)
2021
[i6]
- view
  - electronic edition @ arxiv.org (open access)
  - details & citations
- export record
  dblp key:
  - journals/corr/abs-2111-04738
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/corr/abs-2111-04738
Eduardo Conde-Sousa, João Vale, Ming Feng, Kele Xu, Yin Wang, Vincenzo Della Mea, David La Barbera, Ehsan Montahaei, Mahdieh Soleymani Baghshah, Andreas Turzynski, Jacob Gildenblat, Eldad Klaiman, Yiyu Hong, Guilherme Aresta, Teresa Araújo, Paulo Aguiar, Catarina Eloy, António Polónia:
HEROHE Challenge: assessing HER2 status in breast cancer without immunohistochemistry or in situ hybridization. CoRR abs/2111.04738 (2021)

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.